<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03616015</url>
  </required_header>
  <id_info>
    <org_study_id>2018-A00676-49</org_study_id>
    <nct_id>NCT03616015</nct_id>
  </id_info>
  <brief_title>Dysbiosis and Immune Reconstitution After Allo-HSCT</brief_title>
  <acronym>PARI-DYS</acronym>
  <official_title>Intestinal Dysbiosis and Immune Reconstitution After Allogeneic Hematopoietic Cell Transplantation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Central Hospital, Nancy, France</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Central Hospital, Nancy, France</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Preliminary (proof of concept), monocentric, interventional, prospective, non-randomized and
      analytic trial designed to simultaneously explore intestinal microbiota changes and early
      post-transplant immune reconstitution, and to correlate biological data with clinical data
      (antibiotics use, stress level, GVHD).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is the major curative
      therapeutic approach for hematologic neoplasms. After HSCT, patients have a compromised GI
      mucosal barrier and an altered microbiota, also called dysbiosis. The later could be due to
      conditioning or use of broad-spectrum antibiotics, and could be accentuate by stress
      encountered by patients during their therapy management. Recent data have shown that
      alterations in the intestinal flora are associated with bad outcome, particularly with
      graft-versus-host disease (GVHD), bacteremia, and reduced overall survival
      post-transplantation. How intestinal bacteria can modulate the risk of relapse after HSCT is
      yet unknown. The scientists hypothesize that the variation of some bacterial taxa may
      influence post-transplant immune reconstitution, particularly invariant Natural Killer T
      cells.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 4, 2018</start_date>
  <completion_date type="Anticipated">September 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">January 31, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>quality of iNKT reconstitution after HSCT (good/poor)</measure>
    <time_frame>Day 90,</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>gut microbiota composition</measure>
    <time_frame>Day 0, Day 15, Day 30, Day 90</time_frame>
    <description>relative abundance of intestinal bacterial taxa</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>immune reconstitution after HSCT (other immune cells)</measure>
    <time_frame>Day 15, Day 30, Day 60, Day 90, Day 180, Year 1, Year 2</time_frame>
    <description>quantification of Tregs, MDSC, MAIT, T lymphocytes</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>GVH disease</measure>
    <time_frame>Day 30, Day 60, Day 90</time_frame>
    <description>yes/not</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>use of antibiotics</measure>
    <time_frame>Day 0, Day 15, Day 30, Day 60, Day 90</time_frame>
    <description>yes/not (molecules, delay, posology)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>level of stress</measure>
    <time_frame>Day -8, Day 15, Day 30, Day 90</time_frame>
    <description>test of Cohen</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>level of anxiety</measure>
    <time_frame>Day -8, Day 15, Day 30, Day 90</time_frame>
    <description>test of Spielberger</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>quality of iNKT reconstitution after HSCT (good/poor)</measure>
    <time_frame>Day 15, Day 30, Day 60, Day 180, Year 1, Year2</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Hematopoietic Stem Cell Transplantation</condition>
  <arm_group>
    <arm_group_label>Patient</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>For all patients included in the study, the following interventions will be performed :
several blood samples (quantity collected requiring classification of this study as interventional according to French law)
several fecal samples
anxiety tests
stress tests</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>blood samples</intervention_name>
    <description>20 to 30 ml of blood sample (D0, D15, D30, D60, D90, D180, Y1, Y2)</description>
    <arm_group_label>Patient</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>fecal samples</intervention_name>
    <description>1 g of feces (D-8, D0, D15, D30, D90)</description>
    <arm_group_label>Patient</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Anxiety test</intervention_name>
    <description>Test of Spielberger</description>
    <arm_group_label>Patient</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Stress test</intervention_name>
    <description>Test of Cohen</description>
    <arm_group_label>Patient</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients &gt; 18 years affiliated to a social security system

          -  Patients followed at the hospital of Nancy for a allogeneic hematopoietic cell
             transplantation (HLA matched donor)

          -  Graft of peripheral blood stem cell

          -  GVHD prophylaxis by ciclosporin and antilymphocyte serum +/- mycophenolate mofetil or
             methotrexate.

        Exclusion Criteria:

          -  HIV+ patients

          -  Patients with active HBV or HCV
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Corentine ALAUZET, Dr</last_name>
    <phone>0383153938</phone>
    <phone_ext>+33</phone_ext>
    <email>c.alauzet@chru-nancy.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Marie-Thérèse RUBIO, Pr</last_name>
    <phone>0383153257</phone>
    <phone_ext>+33</phone_ext>
    <email>m.rubio@chru-nancy.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>RUBIO Marie-Thérèse</name>
      <address>
        <city>Vandoeuvre Les Nancy</city>
        <zip>54511</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marie-Thérèse RUBIO, PU-PH</last_name>
      <phone>383153282</phone>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>January 2019</verification_date>
  <study_first_submitted>July 19, 2018</study_first_submitted>
  <study_first_submitted_qc>August 2, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">August 6, 2018</study_first_posted>
  <last_update_submitted>January 30, 2019</last_update_submitted>
  <last_update_submitted_qc>January 30, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">February 1, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>HSCT</keyword>
  <keyword>intestinal dysbiosis</keyword>
  <keyword>immune reconstitution</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dysbiosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

